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INTERMITTENT DIAZEPAM AND
CONTINUOUS PHENOBARBITAL TO TREAT
RECURRENCE OF FEBRILE SEIZURES
A systematic review with meta-analysis
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ABSTRACT - Convulsions triggered by fever are the most common type of seizures in childhood, and 20% to
30% of them have recurrence. The prophylactic treatment is still controversial, so we performed a systematic
review to find out the effectiveness of continuous phenobarbital and intermittent diazepam compared to
placebo for febrile seizure recurrence. Method: Only randomized, double-blind, placebo-controlled trials were
analyzed. The recurrence of febrile seizure was assessed for each drug. Results: Ten eligible clinical trials were
included. Febrile seizure recurrence was smaller in children treated with diazepam or phenobarbital than in
placebo group. Prophylaxis with either phenobarbital or diazepam reduces recurrences of febrile seizures. The
studies were clinical, methodological, and statistically heterogeneous. Conclusion: The effectiveness of
phenobarbital and diazepam could not be demonstrated because clinical trials were heterogeneous, and the
recommendation for treatment recurrence should rely upon the experience of the assistant physician yet.
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Diazepam intermitente e fenobarbital contínuo para tratamento da recorrência de convulsões febris:
uma revisão sistemática com metanálise
RESUMO - As convulsões desencadeadas por febre são muito comuns na infância e 20% a 30% delas apresentam
recorrência. O tratamento profilático, no entanto, ainda é controverso, motivo porque realizamos uma revisão
sistemática para avaliar a eficácia do tratamento da recidiva de convulsão febril com diazepam e fenobarbital
comparados a placebo. Método: Analisamos somente estudos randomizados, duplo-cegos, controlados,
utilizando fenobarbital contínuo ou diazepam intermitente versus placebo. Resultados: Dez ensaios clínicos
foram incluídos. A recorrência de convulsão febril foi menor no grupo das crianças tratadas com diazepam ou
fenobarbital em relação ao controle. Tanto diazepam quanto fenobarbital reduziram as recorrências da
convulsão febril. Os estudos foram clínica, metodológica e estatisticamente heterogêneos. Conclusão: A eficácia
do fenobarbital e diazepam não pôde ser demonstrada nesta metanálise por causa da heterogeneidade dos
ensaios clínicos, e a recomendação para tratamento de recorrência deve basear-se na experiência clínica de
cada médico.
PALAVRAS-CHAVE: tratamento profilático, convulsões febris, diazepam intermitente, fenobarbital contínuo.
Febrile seizures are the most prevalent type of
seizure, occurring in about 2% to 5% of young chil-
dren, and their recurrence varies from 20% to 30%1.
Febrile seizure is defined as convulsions occurring in
children aged 0 to 5 years, with no history of neuro-
psychiatric disorders or with a concomitant neuro-
logical disease. The prognosis is good for the most
patients, but seizures are upsetting to the children
and parents. There are studies demonstrating a re-
lation between the number of febrile seizures, mainly
the complex ones, and the risk for epilepsy2-3. Besides,
recurrent convulsions may be deleterious to intel-
lectual development4.
The prevention of febrile seizures might be benefi-
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cial, but the long-term management is controver-
sial5-7. For some authors, prophylactic use of conti-
nuous phenobarbital prevents recurrence8. Others
consider it of limited or no prophylactic value9. But
they agree that side-effects and no compliance are
common3,9-10. Also intermittent diazepam prophylaxis
has been used, but this treatment is not worldwide
accepted and it has been argued that intermittent
prophylaxis often fails11.
A review of trials published in English showed
that only phenobarbital or valproate has effect in
preventing febrile seizures recurrence and besides
the results, those drugs were not recommended
because of adverse effects. We performed a syste-
matic review including trials published in English and
also in Spanish and Portuguese to analyze the recur-
rence of febrile seizure in children treated with phe-
nobarbital/diazepam and placebo.
METHOD
The electronic search was performed combining the
following key words: febrile convulsion, febrile seizures,
convulsão febril, crisis febriles, convulsión febril, pheno-
barbital, fenobarbital, diazepam and prophylaxis, profila-
xia, profilaxis. The reference research was obtained from
Cochrane Center of Brazil, Medline, Lilacs and Embase.
Other research sources were from letters to experts, thesis
indexed at BIREME/PAHO-WHO (Biblioteca Regional Medi-
cina/Panamerican Health Organization of the World Health
Organization), abstracts sent to Medical Meetings, but not
published. We also have searched over the reference list
of all recovered trials.
 Classification of the trials. We classified the trials accor-
ding to the randomization in A (described as randomized,
description presented), B (described as randomized, des-
cription absent) and C (described as randomized, des-
cription present contrary evidence). Taking in account the
blinding procedure we classified the studies in A (described
as double-blind, description present), B (described as dou-
ble-blind, description absent) and C (described as double-
blind, description present contrary evidence).
We included in this systematic review only placebo con-
trolled trials, with all sample sizes, classified as A or B for
randomization, A or B for blinding, written in English, Por-
tuguese and Spanish. We excluded in this review case re-
ports and trials classified as C for randomization and C for
blinding. We analysed the treatment in three ways: inter-
mittent diazepam compared to placebo; continuous phe-
nobarbital compared to placebo; intermittent diazepam
or continuous phenobarbital compared to placebo.
 Statistical Analysis. The analysis was performed in table
2X2: febrile seizure recurrence (yes or no) and the inter-
mittent use of diazepam (yes or no); febrile convulsion
recurrence (yes or no) and the use of continuous pheno-
barbital (yes or no). The statistical heterogeneity of the
results was evaluated in funnel plot graphics, related to
sample size (Y axis) and calculation of χ2 test, in the N
degrees of freedom, considering N = number of trials
minus 1. To decide for a statistical significant finding it
was used α<5%.
RESULTS
 We identified forty-eight trials published in
English related to continuous use of phenobarbital
and intermittent use of diazepam in the treatment
of recurrences of febrile seizures. Thirty-eigth trials
were excluded, for they were not randomized ones.
Ten randomized clinical trials in English were initially
included in this review, for they fulfilled the inclusion
criteria. Thirty-five trials in Portuguese and Spanish
were found and among them only one was eligible.
Among those eleven trials2,4,6,12-19 classified (Table
1), one trial (Knudsen12) was subsequently excluded
from our statistical analysis, because of the classifi-
cation C for randomization.
Diazepam versus placebo. Comparing the treat-
ment with diazepam versus placebo (Figure 1), the
recurrence risk in febrile convulsion is lower in chil-
dren treated with intermittent diazepam (NNT 17;
95% CI 10 to 85; z=2.47 p<0.01). So for each 17
treated children, one has no recurrence (OR for recur-
rence 0.6; 95% CI 0.40 to 0.90). In the diazepam
group 11.2% (44/393) have recurrence and also
17.1% (68/398) of the placebo group. The results
comparing the trials with diazepam and placebo we-
re heterogeneous (χ2 = 10.19; p<0.01).
Phenobarbital versus placebo. Comparing phe-
nobarbital versus placebo (Fig 1), the recurrence risk
is lower in children treated with continuous pheno-
barbital (NNT 8; CI 95% 5 to 18; z=3.46 p<0.05). If
we treat  8 children with  phenobarbital, comparing
to placebo group, one child would not have recur-
rence (OR for recurrence 0.54; 95% CI 0.38 to 0.76).
In  the phenobarbital group 24.5% (71/290) have
recurrence and also 37.0% (114/308) of the placebo
group. The results comparing the trials with phe-
nobarbital and placebo were heterogeneous (χ2 =
15.40 p<0.01).
Intermittent diazepam or phenobarbital versus
placebo. Comparing the prophylatic effect of phe-
nobarbital or diazepam with placebo (Fig 1), we
found that phenobarbital or diazepam reduces re-
currence risk in febrile convulsion (NNT 12; 95 % CI
8 to 22; χ2 = 25.76 p<0.02), meaning that for each
12 treated children, one has no recurrence. OR for
recurrence is 0.56 (95% CI 0.43 to 0.73; z=-4.23
p<0.02).
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DISCUSSION
The most common treatment for febrile seizures
has been the daily administration of phenobarbital
or intermittent diazepam8,12, a practice that has been
questioned by many authors. Since seventies, several
studies concerning treatment of febrile seizures have
been published, but only 10 trials could be con-
sidered in our analysis, disclosing a lack of good stu-
Fig 1. Odds Rartio (OR) and 95%CI in relation to number of recurrences with treatment Drug vs Placebo.
Table 1. Characteristics of the trials included in this review.
Reference Year Randomization Double- Sample               Loss
Author Number  blind (N) Exclusions N  %
Knudsen 12 1978 C - 195 0 39 20
Camfield 13 1980 B A 79 0 12 15,2
Bacon 14 1981 B A 207 0 69 33,3
Mamelle 15 1984 A - 49 1 3 6,1
Mosquera 16 1987 A - 43 0 4 9,3
Mckinlay 17 1989 B - 101 0 13 12,9
Autret 18 1990 B A 185 0 18 9,7
Farwell  6 1990 A A 217 0 44 20.3
Rosman  2 1993 A A 406 0 105 25,8
Thilothammal 4 1993 A A 60 0 3 5
Uhari 19 1995 A A 180 0 19 10.5
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dies insuring a body of evidence to treat febrile sei-
zures. Four studies (Table 2) comparing intermittent
use of diazepam with placebo were found2,16,18,19.
Autret18, Mosquera16 and Rosman2 demonstrated the
efficacy of diazepam in preventing febrile seizure in
relation to placebo, but the results in Autret and
Mosquera studies were not statistically significant.
Rosman demonstrated that the diazepam treatment
was more effective than placebo in his study, but
more than 20% were lost in follow-up, which could
modify the result significantly. Uhari‘s trial19 showed
no differences between the diazepam and placebo
groups. The analysis of those four trials indicated
that the risk for recurrent febrile seizures decreased
with diazepam comparing to placebo, but the χ2 test
demonstrates that those studies are heterogeneous,
which means that the results concerning to efficacy
of randomized trials with intermittent diazepam the-
rapy are controversial.
Among the studies (Table 3) comparing use of
phenobarbital and placebo, in five ones4,6,13-15 phe-
nobarbital reduced the recurrence risk for febrile sei-
zures. But in 3 studies4,13-15, the relative reduced risk
was not significant. Mckinlay17 showed there was
no difference in recurrence risk between phenobar-
bital and placebo.
The analysis of all studies (Table 4) in this meta-
analytic review demonstrated that the treated group,
either with intermittent diazepam or continuous phe-
nobarbital, when compared with placebo group had
a decreased recurrence risk of febrile seizure. The
results were statistically significant, suggesting that
the therapy is effective in preventing the febrile sei-
zure recurrence. When we compared statistically the
results, the χ2 test showed heterogeneity of the trials,
either due to methodological differences or clinical
intrinsic differences of each study, and three possi-
bilities arise to explain this heterogeneity: answers
that do not agree with the trial quality, sample size
and even clinical heterogeneity. However, in view of
methodological differences of each study design, it
is not possible to make a decision concerning the
efficacy of diazepam or phenobarbital in preventing
febrile seizures based on this systematic review and
mostly on the meta-analytic study.
Clinical heterogeneity detected in those included
Table 2. Trials using diazepam in relation to dose, treatment lasting, administration and follow-up.
Author Dose Frequency Duration of Administration Follow-up
(mg/Kg) (Hours) treatment (months)
(months)
Rosman 0.33 8/8 23 OA 23
Mosquera 0.5 8/8 24 RA 24
Autret 0.2 –0.5 12/12 10.3 OA 10.3
Uhari 0.2 –0.65 8/8 24 RA 24
RA, rectal administration; AO, oral administration during the febrile episode
Table 3. Trials using phenobarbital in relation to dose, duration of treatment, administration and follow-up.
Phenobarbital
Author Dose Duration of Administration Follow-up
(mg/Kg/day)  treatment (months) (months)
Thilothammal 5 12 AO 12
McKinlay 5 3 - 6 AO 24
Farwell 4 – 5 24 AO 24
Mamelle 3 – 4 21 AO 36
Camfield 4 – 5 12 AO 12
Bacon 5 12 AO 12
AO, continuous oral administration
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trials was mostly related to clinical definition of
febrile seizure patients allocated to treatment, age
of patients (below or above 5 years), number of
seizures, duration of seizures, co-morbidities,
abnormal EEG, and doses of medication in the same
drug option. We did not find a study that have
calculated the number of patients necessary to allow
statistical power for a scientific decision on the
effectiveness of the treatment.
In conclusion the present systematic review and
meta-analyses allow us to conclude that there is not
a strong recommendation to treat febrile seizure
either with continuous phenobarbital or with
intermittent diazepam prophylaxis, because of the
design and heterogeneity of the primary studies, but
there is an evidence of potential benefit with the
treatment of both drugs, although it is not possible
to conclude which therapy is better, due to already
mentioned heterogeneity of study design. The
treatment decision should result from appropriate
judgement and experience of the physician, and a
standard trial with a large number of patients should
be done to bring more information over this issues.
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